Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Gut microbial metabolites lower blood pressure in patients with hypertension

Nature Cardiovascular Research volume 2, pages 18–19 (2023) Cite this article

Subjects

Supplementation with the gut microbial-derived metabolites acetate and butyrate has been shown to lower blood pressure in experimental models of hypertension. However, the translational potential of these metabolites has been unexplored. We provide clinical evidence that acetate and butyrate lower blood pressure in untreated patients with hypertension.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Lowing blood pressure by supplementation with HAMSAB.
The alternative text for this image may have been generated using AI.

References

  1. Xu, C. & Marques, F. Z. How dietary fibre, acting via the gut microbiome, lowers blood pressure. Curr. Hypertens. Rep. 24, 509–521 (2022). A review article that presents the latest evidence on dietary fibre and blood pressure.

    Article  Google Scholar 

  2. Kaye, D. M. et al. Deficiency of prebiotic fibre and insufficient signalling through gut metabolite sensing receptors leads to cardiovascular disease. Circulation 141, 1393–1403 (2020). This paper reports on the use of acetate and butyrate to lower blood pressure in an experimental animal model.

    Article  CAS  Google Scholar 

  3. Nakai, M. et al. Essential hypertension is associated with changes in gut microbial metabolic pathways: a multisite analysis of ambulatory blood pressure. Hypertension 78, 804–815 (2021). This paper reports lower levels of SCFA producers and GPR43 in human hypertension.

    Article  CAS  Google Scholar 

  4. Yang, T. et al. Gut dysbiosis is linked to hypertension. Hypertension 65, 1331–1340 (2015). This paper reports lower levels of SCFA producers in experimental hypertension.

    Article  CAS  Google Scholar 

  5. Xie, L. et al. Dietary fibre controls blood pressure and cardiovascular risk by lowering large intestinal pH and activating the proton-sensing receptor GPR65. Preprint at bioRxiv https://doi.org/10.1101/2022.11.17.516695 (2022). This paper reports on a new G-protein-coupled receptor that lowers blood pressure via the fiber–microbiome–SCFA axis.

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Jama, H. A. et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. Nat. Cardiovas. https://doi.org/10.1038/s44161-022-00197-4 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gut microbial metabolites lower blood pressure in patients with hypertension. Nat Cardiovasc Res 2, 18–19 (2023). https://doi.org/10.1038/s44161-022-00204-8

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s44161-022-00204-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology